The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of ViroPharma Inc. (Nasdaq: VPHM) (“ViroPharma” or “the Company”), concerning the Company’s proposed acquisition by Shire Plc (Nasdaq: SHPG) (“Shire”). Under the terms of the proposal, ViroPharma shareholders will receive $50.00 in cash for each share of ViroPharma they own. The entire transaction is valued at approximately $4.2 billion. The investigation is focused on whether ViroPharma’s Board of Directors breached its fiduciary duty in failing to maximize consideration to shareholders, the potential unfairness of the consideration to shareholders, the process by which the Board considered the transaction, and potential conflicts of interest among the Company’s Board members. If you are interested in discussing your rights as a ViroPharma shareholder, or have information relating to this investigation, please contact Finkelstein Thompson’s Washington, DC offices at (877) 337-1050 or (202) 337-8000, or by email at email@example.com. Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our website at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.